Observational studyFrontiers in endocrinology2025
Elevated pre-pregnancy testosterone is associated with gestational diabetes mellitus: an observational cohort study.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Pre-pregnancy testosterone increase may be closely related to the occurrence of gestational diabetes mellitus (GDM). Objective: Our aim is to explain the relationship between pre-pregnancy testosterone levels and the risk of GDM and provide evidence for early clinical warning. Methods: We conducted a retrospective cohort study on 4174 parturient. The exposure factor is pre-pregnancy testosterone, with the primary outcome was GDM (A1+A2) and the secondary outcome was GDM A2. We used trend testing, multivariate logistic regression models, smooth curve fitting, and age and BMI for subgroup analysis and interaction analysis to evaluate the relationship and odds ratio between different pre-pregnancy testosterone levels and GDM risk. Results: Elevated levels of pre-pregnancy testosterone are closely related to the onset of GDM Compared with the control group, women with testosterone levels between Q4 nmol/L had an OR value of 1.76 (95% Confidence Interval: 1.38,2.25) for GDM (A1+A2). The OR value for GDM A2 is 2.26 (95% CI: 1.27,4.00). In terms of sensitivity analysis, it was also observed that elevated pre-pregnancy testosterone increased the risk of GDM, especially in the age<35 and BMI<24 groups. Pre-pregnancy testosterone had a greater effect on GDM A2, with OR values of 1.42 (95%CI: 1.04,1.94) and 1.86 (95% CI: 1.30,2.66). Conclusion: Pre-pregnancy testosterone testing is associated with the risk of developing GDM, and women age<35 or BMI<24 need to pay more attention to pre-pregnancy testosterone. Pre-pregnancy testosterone can serve as a potential biomarker for risk stratification of GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.